Vimarsana
Biggest News Aggregation in the World

Page 2 - Biopharma Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biopharma Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biopharma Development Today - Breaking & Trending Today

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) - Vimarsana News

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human...

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society - Vimarsana News

Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new pooled efficacy and safety analyses from the...

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause - Vimarsana News

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b...

Menopause drug Veozah approved by FDA to treat hot flashes - Vimarsana News

Menopause drug Veozah approved by FDA to treat hot flashes

The Food and Drug Administration has approved a once-a-day pill for uncomfortable hot flashes, chills and sweats associated with menopause.

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause - Vimarsana News

Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...